Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Day One Biopharmaceuticals (DAWN) Assets Average (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Assets Average for 4 consecutive years, with $510.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets Average fell 13.69% to $510.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $510.8 million, a 13.69% decrease, with the full-year FY2025 number at $545.3 million, up 13.74% from a year prior.
  • Assets Average was $510.8 million for Q4 2025 at Day One Biopharmaceuticals, down from $516.4 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $591.8 million in Q4 2024 to a low of $335.9 million in Q2 2022.
  • A 4-year average of $437.7 million and a median of $395.1 million in 2023 define the central range for Assets Average.
  • Biggest YoY gain for Assets Average was 58.98% in 2025; the steepest drop was 13.69% in 2025.
  • Day One Biopharmaceuticals' Assets Average stood at $365.5 million in 2022, then rose by 8.11% to $395.1 million in 2023, then soared by 49.78% to $591.8 million in 2024, then dropped by 13.69% to $510.8 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Assets Average are $510.8 million (Q4 2025), $516.4 million (Q3 2025), and $526.7 million (Q2 2025).